


WHI-P258

Cat. No.:	HY-108419		
CAS No.:	21561-09-1		
Molecular Formula:	C ₁₆ H ₁₅ N ₃ O ₂		
Molecular Weight:	281.31		
Target:	JNK		
Pathway:	MAPK/ERK Pathway		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 31.25 mg/mL (111.09 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.5548 mL	17.7740 mL	35.5480 mL
	5 mM	0.7110 mL	3.5548 mL	7.1096 mL
	10 mM	0.3555 mL	1.7774 mL	3.5548 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.25 mg/mL (8.00 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.25 mg/mL (8.00 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.25 mg/mL (8.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

WHI-P258, a quinazoline compound, binds to the active site of JAK3 with an estimated K_i of 72 μM. WHI-P258 does not inhibit JAK3 and does not affect the thrombin-induced aggregation of platelets even at 100 μM^{[1][2]}.

REFERENCES

[1]. Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res. 1999 Jun;5(6):1569-82.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA